Immunocore Holdings PLC - ADR is a commercial-stage T cell receptor (TCR) biotechnology company. Operating worldwide, the company is engaged in utilising its TCR technology to develop treatments for various types of cancer, infectious diseases, and autoimmune conditions.
Immunocore Holdings PLC works within the biotechnology sector in the specific field of T-cell receptor-based immunotherapies. Through its advanced ImmTAC (Immune mobilising monospecific TCR Against Cancer) technology, the company has a therapeutic focus on providing novel treatment options targeting multiple indications.
Receive news and updates on the IMCR share price by adding this stock to your eToro watchlist.